The Hindu Business Line : Dabur Pharma to invest Rs 300 cr in expansion, R&D

DABUR Pharma Ltd is planning make investments of over Rs 300 crore for expanding its manufacturing capabilities and increasing its research and development activities.

And it is trying to rope in foreign investors including IFC to invest in the company. IFC is exploring a possible equity investment of $15 million in the company.

The proposed investment of Rs 300 crore will be spread over the next three years. While 40 per cent of this would be utilised in expanding manufacturing units, the rest will go towards R&D.

DPL currently has manufacturing facilities in Kalyani (West Bengal), Baddi (Himachal Pradesh) and Bordon (UK) (owned by Dabur Oncology Plc, a 100 per cent subsidiary of DPL).

However, it is now planning to set up a new plant in Baddi as well as expanding its Kalyani facility, which has already been approved by the US Food and Drug Administration.

On the research front, the company is the market leader in oncology formulations and active pharmaceuticals ingredients (API or bulk drugs) in India and exports to over 30 markets across the world.

"The project is to undertake a plan to leverage its manufacturing expertise and its research and development efforts over the last few years and to grow significantly by expanding its international market reach and commercialising new products," said sources.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page